Maxim Upgrades Indaptus Therapeutics To Buy

Maxim analyst has upgraded Indaptus Therapeutics Inc INDP to Buy from Hold with a $16 price target, an upside of over 100%.
Analyst Jason McCarthy says, Indaptus is leveraging the ability of attenuated, non-pathogenic gram-negative bacteria to stimulate both innate and adaptive immune responses for oncology indications and infectious diseases.
In a research note, the analyst tells investors that it is also building on the initial immune therapy, Coley's toxins, with a "modernized, safer, and more effective approach."
McCarthy further states that the key for Indaptus is its cash runway, an experienced management team, and a program in Decoy20 that could potentially be paired with several existing cancer therapeutics.
Related: Why Are Indaptus Therapeutics Shares Shooting Higher On Wednesday?
Price Action: INDP shares are up 3.45% at $7.80 during the market session on the last check Tuesday.

Analyst Calendar